KWANGIL JEONG

Email: abo1q8@r.postjobfree.com

Address: ** ********* *****

City: SHREWSBURY

State: MA

Zip: 01545

Country: USA

Phone: 508-***-****

Skill Level: Management

Salary Range: 125

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

KWANG-IL JEONG, DVM, PHD.

508-***-**** * abo1q8@r.postjobfree.com

SENIOR SCIENTIST - IMMUNOLOGY/PATHOLOGY

Infection & Immunity Microbiology Design & evaluation of therapeutics (Antibody/Vaccine)

Cell- & antibody-based Immunoassays Biomarkers to inflammatory responses

Diagnostic Molecular Biology & Pathology Animal Model Development

SUMMARY OF QUALIFICATIONS

Expertise achieved through over 12 years of research experience in the cellular and humoral immunity: (1) analysis of immune cell phenotypes, cytokine/chemokine/antibody responses to infections or vaccinations; (2) immunological techniques (e.g., FACS, ELISPOT, ELISA, Proliferation assay, Depletion assay, Neutalization assay; In vitro culture/stimulation of primary mononuclear cells (MNCs); Isolation of MNCs from local and systemic lymphoid tissues and blood).

In-depth knowledge and skills in development of therapeutic vaccines and antibodies and assessment of their safety, immunogenicity, and protective efficacy against challenge with viral or bacterial pathogens in various animal disease models (gnotobiotic piglet model, non-human primate BHS infection model, murine Staphylococcal wound model, rat endocarditis model, infant rat bacteremia, sepsis model, etc.); Resourceful professional experiences in design and execution of in vivo studies on the therapeutic antibodies and vaccines, focused on target identification & validation, and mechanism of action (MOA), using .

Broad range of microbiological techniques to determine virulence and pathogenicity of viral and bacterial infectious agents, and highly knowledgeable of host immune responses, against systemic infections and, in particular, local (respiratory/gastro-intestinal mucosa) infections.

Skilled in development and validation of cell/antibody-based immunoassays (e.g., ELISA, FACS, ELISPOT, ECL detection) and experienced in other in vitro assays (e.g., Myeloperoxidase assay-MPO, Luminex, Opsonophagocytic assay-OPA).

Marked scientific skills and knowledge in cell & tissue analysis, diagnostics cellular/molecular biology, along with a set of skills in the histology/histopathology, such as immunohistochemistry (IHC), immunocytochemistry, and in situ hybridization (ISH).

Excellent in experimental design and data analysis & interpretation, and familiar with softwares (e.g. Flowjo and Cell-quest for Flow cytometry; CTL ImmunoSpot(R) analyzer for ELISPOT; SoftMax Pro for ELISA; Kodak 1D3.6 for gel-image analysis; SAS, PRISM, and SigmaPlot for statistics, etc.).

Strong track records (publications & presentation of scientific results) and significant contribution to regulatory filings and writing SOPs, anima use protocols (AUP) and other research protocols.

Published senior scientist who works well independently and thrives in collaborative team environments; Proven leadership experience including background training, mentoring, and supervising junior researchers and lab associates.

Valued and respected associate recognized for superior work ethic, strong attention to detail, and innovative approach to problem solving.

AREAS OF EXPERTISE / LABORATORY SKILLS

Immunology: Analysis of innate and acquired cellular/humoral immune responses to infection or vaccination; Phenotyping/sorting for assessing surface markers and secreted proteins of mononuclear cells (MNC) by fluorescence activated cell sorting (FACS), ELISA and ELISPOT with primary immune cells (human and animals),MNC culture supernatants, and others (feces, serum, gut contents, etc.); Isolation of MNCs from intestines, mesenteric lymph nodes, spleen, and blood; In vitro assays (e.g., magnetic separation/depletion assay, proliferation assay, etc.) with MNCs; Mode of action on neutralization of human monoclonal antibodies (HuMAbs) against Shigatoxins (Stxs); HeLa cell survival assay; Bio-distribution/clearance kinetcs of immune complex; Analysis of biomarkers for host immune responses (e.g., antibodies, cytokines, chemokines, myeoloperoxidase, etc.) by using ELISA, multi-plex Luminex, RT-PCR, myeloperoxidase assay, etc.

Vaccines: Design and development of attenuated live vaccines, DNA vaccines, non-replicating subuint vaccines for viral and bacterial enteric pathogens; validation of protective efficacy and side effects of vaccine candidates in animal models and in vitro assays (e.g., ELISA, ELISPOT, FACS, Neutralization, OPA, etc.); Vaccination strategies (immunogeneicity, doses, frequency, routes; age, etc.); Biomarkers of protection parameters such as cellular/humoral immune factors; Influence of maternal antibodies on vaccine application.

Pathology and Histology: Histopathological evaluation related to infections, toxifications, cancer, and safety evaluation potentially caused by therapeutic portiens (e.g., vaccines and antibodies); Specialty in pathological diagnosis of cancers; immunofluorescent staining; in situ hybridization (ISH); immunohistochemistry (IHC); immuno-electron microscopy; scanning electron microscopy (SEM); and confocal laser scanning microscopy. Routine pathological techniques (collection of tissue and biopsy samples; processing; paraffin-embedding; cryo-sectioning; H&E, special staining; microscopic examination, etc.).

Infectious Diseases: Intense experience with many BL2 and BL3-level pathogens (Influenza virus, Human rotavirus, Respiratory syncytial virus; Escherichea coli, Shigella species, Mycoplasma pulmonis; Mycobacterium tuberculosis; Staphylococcus aureus, etc.); Host-pathogen interaction; Cell culture immuno-fluorescence (CCIF) assay; Colony forming assays; Plaque reduction assay; Bacteria/virus culture and purification; Design/production/purification of virus-like particles (VLP); Culture of primary cells or cell lines; Development and characterization of animal disease models for infectious diseases; and endotoxin test.

Molecular Biology: DNA/RNA extraction and purification; Quantitative RT-PCR; Electrophoresis; Western blotting; ECL detection; In vitro cell-free protein translation; and Apoptosis signaling; Cell culture (human/animal immune cells; cell-lines, such as MA104 cell, U937 cell, Jurkat cell, HeLa cell, Sf9 cell, etc.); Luminex; Labeling proteins / antibodies with fluochromes/biotin; pBlueBac 4.5 system.

Radiology and laboratory animals: Labeling proteins or cells with Thymidine (3H) and Iodine (125I) for in vivo or in vitro bio-kinetics or cell proliferation assay; In vivo techniques with mice, rats, and gnotobiotic piglets, non-human primates; in vivo imaging system (IVIS), ultra sound imaging, hematology (Advia); inoculation; blood collection, and tissue sampling/processing. Development and characterization of animal disease models for assessment of the safety and efficacy of therapeutics.

EDUCATION

UNIVERSITY OF TOKYO, Tokyo, Japan : PhD in Veterinary Pathology & Immunology * 2000

* Thesis: Morphological and functional characteristics of membranous (M) cells in nasal-associated lymphoid tissue (NALT) in rat

SEOUL NATIONAL UNIVERSITY, Seoul, Korea : Master of Science (MS) in Veterinary Pathology * 1995

* Thesis: Specific binding affinity of Mycoplasma pulmonis to nasal epithelium in the nasal-associated lymphoid tissue (NALT) of rat

Doctor of Veterinary Medicine (DVM) * 1991

SEOUL NATIONAL UNIVERSITY, Seoul, Korea : Bachelor of Science (BS) in Veterinary Medicine * 1991

* Areas of emphasis: immunology, pathology, pharmacology, microbiology, physiology, and toxicology, infectious diseases, oncology.

HONORS & AWARDS

* Scholarship, Rotary Yoneyama Memorial Foundation, Inc., 1998-2000

* Science Scholarship, The Iwatani Naoji Foundation, 1997-1998

PROFESSIONAL AFFILIATIONS

* American Society for Microbiology (ASM),2007-Present

* The Society for Mucosal Immunology (SMI), 2002-Present

* American Society of Virology (ASV, full member), 2001-Present

* The American College of Veterinary Pathologists (ACVP), 1999-Present

* The Japanese Society of Pathology, 1999-2000

* Japanese Association for Laboratory Animal Science, 1998-2000

PROFESSIONAL EXPERIENCE

PFIZER - VACCINE RESEARCH EAST, Pearl River, NY Apr, 2011-Present

Senior scientist

Lead an animal modeling team for Staphylococcal infection and assessment of 4Ag-Staph vaccines. Organized personnel (CM staffs, preclinical scientists, animal care staffs, surgeons) and planned/managed in vivo studies (wound surgery, endocarditis surgery, ultrasound imaging, in vivo bioluminescence or fluorescence imaging study-IVIS) and arranged/executed in vitro assays (myeloperoxidase assay, cytokine luminex, hematology, bacterial culture, bacterial challenge preparation, Gram and IFA staining of tissue stamps/ cryo-sections, etc.).

Key Successes

* Developed and characterized animal diseas models (murine Staphylococcal wound infection; murine and NHP intra-nasal infection of beta-hemolytic Streptococcus, BHS; rat endocarditis; infant rat bacteremia; Staphylococcal sepsis, etc.): Completed animal modeling (infection dosage, duration, bacterial counting, sample/tissue processing and assessment) of Staph wound infection, which is now adopted for vaccine efficacy studies.

* Lead a team as primary investigator and played a key role in vaccine protection studies with Staph wound infection model, by preparing animal use protocols (AUPs) and organizing /communicating with several lab personnel for surgeries, vaccination, bleeds, challenge, tissue harvest, tissue homogenization/culture, etc.

* Identified valuable biomarkers to assess the inflammatory responses and cytokine profiles in local tissues and blood stream by emplementing several technologies (Multi-plex luminex, Myeloperoxidase assay, Advia-hematological analysis, immunofluorescent staining on tissue stamps/cryo-sections).

* Learned communication/organization/management skills while leading the project which frequently takes multi-lab participation.

BIOGEN IDEC - NEUROBIOLOGY/T CELL IMMUNITY, Cambridge, MA Nov, 2010-Apr, 2011

Senior Associate Scientist III (contractor via Integrated Resources, Inc.)

Developed effective immuno-assays to assess T cell responses to JV virus infection in humans, critical indicators to predict the risk factor of PML (Progressive multifocal leukoencephalopathy). PML is a rare and usually fatal viral disease that is characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (multifocal).

Lead day to day laboratory experiments (purification and in vitro culture of human peripheral blood mononuclear cells; peptide binding/presentation assay using pentamer staining/FACS analysis, etc.).

Key Successes

* Standardized/established sensitive immunoassays (e.g., ELISPOT, FACS, Antibody Neutralization, etc.), however, with a main focus in development of ELISPOT to assess the cytokine responses by human PBMCs following in vitro stimulation with JC virus peptides.

* Reported that the ELISPOT assay is the most sensitive and reliable assays to measure JC virus peptide-specific cytokine responses among the assays tested. Found that supplement of certain cytokines during in vitro stimulation promotes T cell responses 100~500 folds higher.

TUFTS UNIVERSITY - BIOMEDICAL SCIENCES, CUMMINGS SCHOOL OF VETERINARY MEDICINE, North Grafton, MA Aug, 2005-Sep, 2010

Food and Waterborne Diseases Integrated Research Network (FWD IRN, Microbiology/Botulinum Research Unit (MBRU)

Senior Scientist / Project Leader of NIH/NIAID Grant (NO1-AI-30050)

Managed 2 NIH-funded projects totaling $2.8M focused on therapeutics for the diseases & complications caused by enteric pathogens: one grant for development of antibody therapeutics of HUS (Hemorrhagic Uremic Syndrome), fetal/acute renal disease in human caused by E. coli and another NIH grant for development and evaluation of attenuated live vaccines for shigellosis caused by Shigella species, main causative of bacterial diarrhea in children. Hold sole responsibility for charge of grant reports (quarterly, semi-annual, and annual progress reports, and final summaries). Lead day to day laboratory operations, including supervising research assistants, monitoring budgets, and ensuring efficiency use of resources. Conduct statistical analysis of experimental data and prepare manuscripts for publication in leading scientific journals.

Key Successes

* Played critical role in securing NIH funds, including renewal of Shigella project ($0.8M, 2 years) and 2 new grants for E. coli projects ($1.5M, 2 years).

* One human monoclonal antibody (5C12) for treatment of HUS approved to move onto pre-clinical trials based on our findings in the E. coli project (e.g., Neutralizing efficacy, Bio-kinetics of toxin clearance, and Influence of FcR and C3 on detoxification).

* Our efforts in the Shigella project provided strong basis for live attenuated Shigella vaccine candidates (e.g., WRSs3; WRSd1 strains), approved by NIH and currently in clinical trial phases.

* Development of the antibody-based immunoassays (e.g., ELISA, Immunocytochemistry) to measure the biomarkers/proteins (e.g., cytokines, antibodies, toxins, etc.) in various types of samples (e.g., culture supernatants; sera; feces; gut contents) using the monoclonal antibody (5C12), and other candidates.

* Successful establishment of Shigellosis animal model, gnotobiotic piglet, which is recognized as first animal model over the world, micking disease the features of Shigellosis seen in humans. This animal model has been utilized in subsequent studies (safety/efficacy of Shigella vaccines).

* Engineered and evaluated the attenuated Shigella vaccine candidates (8 strains) and the derivatives (5 strains). Potential adverse effects and the protective efficacy of these strains were examined by measuring the inflammatory cytokine profiles (ELISA techniques), assessing the tissue damage (histopathology/immunohistochemistry methods), and through microbiological analysis (e.g., shedding in the feces, colonization in the gastrointestinal tract, and bacteremia) & monitoring clinical symptoms.

Primary Research Focus

Generation, mass-production, and purification of nineteen human monoclonal antibodies (HuMAbs) against Shigatoxins (e.g., Stx1, Stx2), a major cause of HUS.

Evaluation of neutralization/protective efficacy and potential adverse effects of 19 HuMAbs in animal models (e.g., knock-out mouse strains, gnotobiotic piglets) and in vitro assays (Western blot, ECL detection, Flow cytometry, ELISA, HeLa cell survival assay, Protein translation assay using the Reticulocyte lysate, Apoptosis induced by Shigatoxins, Fluorescent microscopy, Immunoelectron microscopy).

Investigation on the Bio-kinetics of detoxification mediated by HuMAbs, and formation/clearance of immune complexes (Stx/HuMAb), by using Enzyme Immunoassay (e.g, Quidel CIC-C1q, ELISA) and radio-isotope (Iodine) labeling techniques, and the Roles of immunological factors (e.g., FcgR & C3 complement) in detoxification/clearance mediated by HuMAbs in knock-out mouse strains.

Development and characterization of an animal model that precisely mimic disease features of human Shigellosis, and study on the pathogenesis of Shigellosis in the animal model.

Evaluation in the animal model of the potential adverse effects and the protective efficacy of live attenuated Shigella vaccine candidates, by examining the inflammatory cytokine profiles, histopathology/tissue damage, and clinical symptoms.

Development of in vitro assays (e.g., Mass production & Purification of HuMAbs; HeLa cells assay & Rabbit reticulocyte lysate/Cell-free protein translation system to evaluate the neutralization efficacy of HuMAbs; Immune-complex formation; Iodination & Biotinylation of antibodies & toxins, etc.) and in vivo experiments (e.g., Survival assays to confirm the protective efficacy of HuMAbs in several knock-out mouse strains and gnotobiotic piglets; Metabolism/Localization and clearance mechanism of immune-complexes (Toxin/HuMAbs) in the tissues and blood stream).

Establishment of the SOPs, including Standard scoring system for diarrhea in gnotobiotic (Gb) piglets following Shigella infection; Blood collection method from Gb piglets inside sterile isolators; Radio-labeling (Iodination) procedures of Shigatoxins (Stxs); In vitro protein translation system using rabbit reticulocyte lysate; Immunohistochemistry for detection of bacterail antigens in paraffin-sections; ELISA protocols for evaluation of cytokines, antibodies, and toxins).

OHIO STATE UNIVERSITY - VIROLOGY & VACCINE IMMUNOLOGY, FOOD ANIMAL HEALTH RESEARCH PROGRAM, Wooster, OH 2000-2005

Vaccine Development for Prevention of Human Rotaviruses (HRV); Viral Pathogenesis

Post-Doctoral Researcher / Key Investigator of multiple NIH/NIAID Grants (R01A133561; R01A137111; R01A13356; R01A1047393)

Supported multiple NIH projects on construction/assessment of vaccines against human rotavirus (HRV), major pathogen responsible for infantile gastroenteritis worldwide and cause of 500,000 deaths annually in children under 5 years of age. Assisted advisor in preparing grant reports and proposals. Trained technicians and students on lab protocols and research practices. Our experimental data on HRV vaccines and pathogenesis have been invited to many of academic conferences and published in 10 major journals.

Key Successes

* Recognized as first scientist to develop and apply cell/antibody-based immunoassays (ELISA, ELISPOT, FACS, Proliferation assay) to assess acquired immune responses (e.g., cytokines, antibodies, immune cell phenotypes) to HRV vaccine candidates: FACS analysis of MNC subsets and expression of CD25 (activation marker), FACS and ELISPOT assays for analysis of the intra-cellular or/and secretory cytokine profiles. Standardized proliferation assays using Thymidine, BrdU, or CFSE during in vitro stimulation.

* Constructed stable non-replicating virus-like particle (VLP) vaccines, such as double-layered 2/6-VLPs, triple-layered 2/6/4/7-VLPs expressed in baculovirus by using pBlueBac 4.5 system. The 2/6-VLP vaccine is one of the most efficacious HRV vaccines ever reported. Mass-produced VLP vaccines in Spodoptera frugiperda (Sf9) cells and purified VLP vaccines.

* Contributed significantly to the in vivo studies in an animal model (gnotobiotic piglet) on viral pathogenesis, protective efficacy & immunogenicity of HRV vaccine candidates, and cytokine profiles as potential correlates with protective immunity.

Primary Research Focus

Analysis of the immunological factors (cellular/humoral) contributing to the protective immunity induced by HRV vaccine candidates.

Development of in vitro assays to determine T-cell responses by flow cytometry, ELISA, ELISPOT, and confocal microscope.

Evaluation of various HRV vaccines (e.g., VLP vaccines, DNA vaccine, etc.) and vaccination regimes in animal model and in vitro assays. Best protective efficacy was achieved via intra-nasal boosting with 2/6-VLP vaccine, which consisted of viral proteins 2 and 6 (2/6-VLP) incorporated into ISCOM (Immuno-stimulating Complexes), when combined with oral priming dose of attenuated HRV. ISCOM was used as adjuvant and carrier to incorporate VLPs on surface and final products resemble structure of native human rotavirus.

Further, our studies clarified pathogenesis of virulent HRV, especially viremia and cytokine responses, and influence of maternal cytokines on vaccination strategy.

UNIVERSITY OF TOKYO, Tokyo, Japan 1997-2000

Teaching Assistant / Tutor - Department of Veterinary Pathology

SEOUL NATIONAL UNIVERSITY, Seoul, Korea 1994-1995

Teaching Assistant - Department of Veterinary Medicine (Pathology)

MILIARY TRAINING & SERVICES, Korea 1988-1993

Additionally, completed 2 years of R.O.T.C. training, and served in Army; retired as first lieutenant and specialized in food inspection and public hygiene.

ADDITIONAL RESEARCH INITIATIVES MS / PhD research topics

Membranous (M) cells in the nasal-associated lymphoid tissue (NALT). 1993-2000

NALT is known as only well-organized mucosal-associated lymphoid tissue (MALT) in upper respiratory tract of rodents and also regarded as equivalent of Waldeyer`s rings in humans. Elucidated anatomical and immunological features of M cells, which are cell-type present in follicle-associated epithelium (FAE) covering underlying lymphoid tissues; sampled antigens using various techniques, such as immuno/lectin-histochemistry, electron microscopy, inhalation system, and confocal laser scanning microscopy. M cells are now considered attractive target sites for vaccine/drug delivery through mucosal tissues. These studies were published as the first major scientific articles in the world, providing the detailed features of M cells in NALT (Exp Anim 1999, 48, 23-29; J Anat 2000, 196, 443-451; J Vet Med Sci 2002, 64, 535-538).

Flow cytometric analysis of intra-epithelial lymphocytes in mouse small intestines. 1996-2000

Intra-epithelial lymphocytes (IELs) are known as primary immune cells in charge of immunological surveillance throughout mucosa. Our research revealed different IEL subsets are harbored in respective segments of small intestines, depending on several factors (e.g., age, sex, strains, nutritional condition, gut segments, etc.), which provided convincing evidence that immune system in intestinal mucosa is unique and differ markedly in T cell composition from systemic lymphoid tissues (6 publications on the IELs; refer to the publication list).

PEER-REVIEWED PUBLICATIONS

M Cell and FAE-related Articles

1. Kwang Il Jeong, Koji Uetsuka, Hiroyuki Nakayama, Kunio Doi. Glycoconjugate Expression in Follicle-Associated Epithelium (FAE) Covering the Nasal-Associated Lymphoid Tissue (NALT) in Specific Pathogen-Free and Conventional Rats. Experimental Animals. 1999; 48 (1), 23-29.

2. Kwang Il Jeong, Hodaka Suzuki, Hiroyuki Nakayama and Kunio Doi. Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional evironment-adapted (SPF-CV) rats. Journal of Anatomy. 2000; 196 (3), 443-451.

3. Suzuki H, Jeong KI, Okutani T, Doi K. Regional variations in the number and subsets of intraepithelial lymphocytes in the mouse small intestine. Comparative Medicine. 2000; 50(1), 39-42.

4. Hodaka Suzuki, Kwang Il Jeong, Taichi Okutani, Kunio Doi. Regional variations in the distribution of small intestinal intraepithelial lymphocytes in three inbred strains of mice. Journal of Veterinary Medical Science. 2000; 62(8), 881-887.

5. Suzuki H, Jeong KI, Doi K. Regional variations in the distribution of small intestinal intraepithelial lymphocytes in alymphoplasia (aly/aly) mice and heterozygous (aly/+) mice. Immunological Investigations. 2001; 30(4), 303-312.

6. Suzuki H, Jeong KI, Doi K. Regional variations in the distributions of small intestinal intraepithelial lymphocytes (IELs) in BALB/c nu/+, ad nu/nu Mice. Comparative Medicine. 2001; 51(2), 127-133.

7. Hodaka Suzuki, Kwang Il Jeong, Kikuji Itoh, Kunio Doi. Regional variations in the distribution of small intestinal intraepithelial lymphocytes in germ-free and specific pathogen-free mice. Experimental and Molecular Pathology. 2002; 72 (3), 230-235.

8. Hodaka Suzuki, Kwang Il Jeong, Kunio Doi. Age-related changes in the regional variations in the number and subsets of intraepithelial lymphocytes in mouse small intstine. Developmental and Comparative Immunology. 2002; 26 (6), 589-595.

9. Kwang-il Jeong, Yong-sung Sohn, Kyoungkyu Ahn, Changsun Choi, Dong Un Han, and Chanhee Chae. Lectin histochemistry of Peyer`s patches in the porcine ileum. Journal of Veterinary Medical Science. 2002; 64 (6), 535-538.

PEER-REVIEWED PUBLICATIONS (CONTINUED)

HRV Vaccine-related Articles

1. Iosef C, Nguyen TV, Jeong KI, Lovgren-Bengtsson K, Morein B, Kim Y, Chang K-O, Azevedo MSP, Yuan L, Nielson P, Saif LJ. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine. 2002; 20 (13-14), 1741-1753.

2. Nguyen TV, Iosef C, Jeong KI, Kim Y, Chang K, Lovgren-Bengtsson K, Morein B, Azevedo MS, Lewis P, Nielsen P, Yuan L, Saif LJ. Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs. Vaccine. 2003; 21 (25-26), 4059-4070.

3. A. M., Gonzalez, T. V., Nguyen, M. S. P. Azevedo, K. Jeong, F. Agarib, C. Iosef, K. Chang, K. Lovgren-Bengsson, B. Morein and L. Saif. Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particles (VLP) boosting with ISCOMs. Clinical and Experimental Immunology. 2004; 135, 361-372.

4. Azevedo MS, Yuan L, Jeong KI, Gonzalez A, Nguyen TV, Pouly S, Gochnauer M, Zhang W, Azevedo A, Saif LJ. Viremia and nasal and rectal shedding of rotavirus in gnotobiotic pigs inoculated with Wa human rotavirus. Journal of Virology. 2005; 79 (9), 5428-5436.

5. Lijuan Yuan, Marli S.P. Azevedo, Ana M. Gonzalez, Kwangil-il Jeong, Trang Van Nguyen, Peggy Lewis, Cristiana Iosef, John E. Hermann and Linda J. Saif. Mucosal and systemic antibody responses and protection induced by a prime/boost rotavirus-DNA vaccine in a gnotobiotic pig model. Vaccine. 2005; 23 (30), 3925-3936.

6. Azevedo MSP, Yuan L, Pouly S, Gonzales AM, Jeong KI, Nguyen TV, Saif LJ. Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus. Journal of Virology. 2006; 80 (1), 372-382.

7. Nguyen TV, Yuan L, P Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ. Low titer maternal antibodies can both enhance and suppress B cell responses to a combined live attenuated human rotavirus and VLP-ISCOM vaccine. Vaccine. 2006; 24 (13), 2302-2316.

8. Nguyen TV, Yuan L, Azevedo MS, Jeong KI, Gonzalez AM, Iosef C, Lovgren-Bengtsson K, Morein B, Lewis P, Saif LJ. High titers of circulating maternal antibodies suppress effector and memory B-cell responses induced by an attenuated rotavirus priming and rotavirus-like particle-immunostimulating complex boosting vaccine regimen. Clinical and Vaccine Immunology. 2006; 13 (4): 475-485.

9. Trang V. Nguyen, Lijuan Yuan, Marli S.P. Azevedo, Kwang-Il Jeong, Ana-Maria Gonzalez and Linda J. Saif. Transfer of maternal cytokines to suckling piglets: In vivo and in vitro models with implications for immunomodulation of neonatal immunity. Veterinary Immunology and Immunopathology. 2007; 117(3-4): 236-248.

10. Marli S.P. Azevedo, Ana Maria Gonzalez, Lijuan Yuan, Kwang-il Jeong, Cristiana Iosef, Trang Van Nguyen, Karin Lovgren-Bengtsson, Bror Morein and Linda J. Saif. Oral versus intranasal prime/boost regimen using attenuated HRV or 2/6VLP with ISCOM influences protection and antibody secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clinical and Vaccine Immunology. 2010; 17(3): 420-428.

PEER-REVIEWED PUBLICATIONS (CONTINUED)

Bacterial Vaccine and Pathogenesis-related Articles

1. Harish K. Janagama, Kwang-il Jeong, Vivek Kapur, Paul Coussens, and Srinand Sreevatsan. Cytokine responses of bovine macrophages to diverse clinical Mycobacterium avium subspecies paratuberculosis strains. BMC Microbiology. 2006; 6 (10), 1-12.

2. Barnoy, S., KI Jeong, R. F. Helms, A. E. Suvarnapunya, R.T. Ranallo, S. Tzipori, M.M. Venkatesan. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine. 2010; 28(6): 1642-1654.

3. Kwang-il Jeong, Q. Zhang, J. Nunnari, S. Tzipori. A piglet model of acute gastroenteritis induced by Shigella dysenteriae type 1. Journal of Infectious Diseases. 2010; 201(6): 903-911.

4. Kwang-il Jeong, Saul Tzipori, Abhineet Sheoran. Stx2- but not Stx1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing Stx1 and Stx2. Journal of Infectious Diseases. 2010: 201(7): 1081-1083.

5. Kwang-il Jeong, Susan Chapman-Bonofiglio, Pradeep Singh, Jongo Lee, Saul Tzipori and Abhineet Sheoran. In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunology. 2010; 11: 16. (doi:10.1186/147*-****-**-**).

6. Abhineet S, Kwang-il Jeong, Mukherjee J, Wiffin A, Singh P, Tzipori S. Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice. BMC Immunol. 2012 Jun 1; 13:27.

7. Kwang-il Jeong, Jean Mukherjee, Saul Tzipori, Abhineet Sheoran. The influence of complement 3 and FcR on the clearance of immune complexes formed between Shiga toxins (Stx) and Stx-specific human monoclonal antibodies in the knockout mouse models. Manuscript under preparation.

8. Kwang-il Jeong, S. Barnoy, M. Venkatesan, S. Tzipori. Immune responses and histopathology in gnotobiotic piglets following infection with attenuated live vaccine candidates (WRSS1, WRSs3) of Shigella sonnei. Manuscript under preparation.

9. Kwang-il Jeong, M. Venkatesan, S. Tzipori. Evaluation of potential side-effects by live vaccine candidates of Shigella dysenteria type 1 (WRSd1, WRSd3, WRSd5) safety: Clinical symptoms, cytokine responses, and histopatholgy in the gnotobiotic piglet. Manuscript under preparation.

PRESENTATIONS

1. Kwang Il Jeong, Koji Uetsuka, Hiroyuki Nakayama, and Kunio Doi. Glycoconjugate Expression in Follicle-Associated Epithelium (FAE) Covering the Nasal-Associated Lymphoid Tissue (NALT) in Specific Pathogen-Free and Conventional Rats. Japanese Association for Laboratory Animal Science (45th). Matsumoto, Nagano, Japan. May 28-30, 1998. (#PG-51).

2. Hodaka Suzuki, Taichi Okutani, Kwang Il Jeong, Kunio Doi. Effects of Fasting on the Subsets of the Small Intestinal Intraepithelial Lymphocytes (IELs) in Mice. The Japanese Society of Veterinary Science (127th). Azabu, Sagamihara, Japan. April 2-4, 1999. (#J-P3).

3. Kwang Il Jeong, Hiroyuki Nakayama, and Kunio Doi. Ultrastructural Study for Follicle-Associated Epithelium of Nasal-Associated Lymphoid Tissue under Different Age and Environment. The Japanese Society of Pathology (88th). Tokyo, Japan. April 6-8, 1999.

4. Hodaka Suzuki, Kwang Il Jeong, Taichi Okutani, Kunio Doi. The Differences of Intraepithelial Lymphocytes (IELs) Subsets Distributed in the Proximal, Middle and Distal Parts of the Small Intestine. Japanese Association for Laboratory Animal Science (46th). Ichikawa, Japan. May 20-22, 1999. (#PH-30).

5. Kwang Il Jeong, Hodaka Suzuki, Hiroyuki Nakayama, and Kunio Doi. Differential Adherence and Proliferation Patterns of Epithelium Overlying NALT and GALT. The American College of Veterinary Pathologists (50th). Chicago, USA. November 16-19, 1999.

6. Hodaka Suzuki, Kwang Il Jeong, and Kunio Doi. Regional Variations in the Number and Subsets of Small Intestinal Intraepithelial Lymphocytes (IELs) in Euthymic and Athymic Mice. The American College of Veterinary Pathologists (50th). Chicago, USA. November 16-19, 1999.

7. Kwang Il Jeong, Hodaka Suzuki, Hiroyuki Nakayama, Kunio Doi. Binding affinity of inhaled materials to and transport of them by M cell in NALT of rat. The Japanese Society of Veterinary Science (129th). Tsukuba, Japan. April 4-6, 2000. (#B-P12).

8. Hodaka Suzuki, Kwang Il Jeong, Taichi Okutani, Kunio Doi. The Difference of Distribution of Intraepithelial Lymphocytes (IELs) Subsets in the Small Intestine among Three Mouse Strains. The Japanese Society of Veterinary Science (129th). Tsukuba, Japan. April 4-6, 2000. (#D-I19).

9. Hodaka Suzuki, Kwang Il Jeong, and Kunio Doi. Different Distribution of Intraepithelial Lymphocytes (IELs) in the small intestines depending on the Intestinal Segments and the Influence of Thymus on it. Japanese Association for Laboratory Animal Science (47th). Yokohama, Japan. May 21-23, 2000. (#C-2).

10. Hodaka Suzuki, Kwang Il Jeong, and Kunio Doi. Influence of the Intestinal floras on the Distribution of Intraepithelial Lymphocytes (IELs) in the small intestines of mice. Japanese Association for Laboratory Animal Science (48th). Yokohama, Japan. May 8-12, 2001. (#P-63).

11. Hodaka Suzuki, Kwang Il Jeong, Kunio Doi. Changes in the Itraepithelial (IEL) Lymphocyte Subsets in the Small Intestines through the Ages of Mice. The Japanese Society of Veterinary Science (132nd). Morioka, Japan. October 6-8, 2001. (#PS-4029).

12. Kwang Il Jeong, C. Iosef, T. Nguyen, Y. Kim, K. Chang, K. Lovgren-Bengsson, B. Morein, L. Saif. Lymphoproliferative responses in gnotobiotic pigs inoculated orally with attenuated human rotavirus (AttHRV) and/or 2/6-rotavirus-like particles (VLP) with immuno-stimulating complexes (ISCOM). American Society for Virology, Annual Meeting (20th). University of Wisconsin-Madison, Wisconsin, USA. July 21-25, 2001. (# 39-9).

13. T. V. Nguyen, C. Iosef, K. Jeong, Y. Kim, K. Lovgren-Bengtsson, B. Morein, P. Lewis, P. Nielsen, M. Azevedo & L. J. Saif. Antibody responses to oral rotavirus-like-particles (VLP2/6) with immunostimulating complexes and attenuated rotavirus vaccines in gnotobiotic pigs. Am.Society for Virology, Annual Meeting (20th). University of Wisconsin-Madison, WI, July 21-25, 2001. (# 56-3).

14. C. Iosef, T. V. Nguyen, K. Jeong, Y. Kim, K. Lovgren-Bengtsson, B. Morein, P. Nielsen, M. Azevedo & L. J. Saif. Analysis of antibody secreting cell responses and protection to Wa human rotavirus (HRV) in gnotobiotic pigs immunized with attenuated Wa HRV (AttHRV) and 2/6-rotavirus-like-particles (VLP) administrated with immuno-stimulating complexes (ISCOM). American Society for Virology, Annual Meeting (20th). University of Wisconsin-Madison, Wisconsin, USA. July 21-25, 2001. (# 56-4).

15. Marli Azevedo, Cristiana. Iosef, Kwang-il Jeong, Ana Maria Gonzalez, Faiz Agarib, Kyeong-ok Chang, Karin Lovgren-Bengtsson, Bror Morein, Paul Nielsen, Trang Van Nguyen & L. J. Saif. Antibody secreting cell responses and protection in gnotobiotic pigs vaccinated orally with attenuated rotavirus and intranasally with 2/6-rotavirus-like-particles and immunostimulating complexes. OARDC Annual Conference. The Ohio State University, Ohio, USA. April 23, 2002.

16. M. Azevedo, C. Iosef, K. Jeong, T. Van Nguyen A. Gonzalez, Y. Kim, F. Agarib, L. J. Saif. Rotavirus and rotavirus-like particle (VLP) vaccines with immunostimulating complexes (ISCOM) as a prime/boost strategy induce intestinal IgA antibody secreting cells and protective immunity to human rotavirus in gnotobiotic pig disease model. Society for Mucosal Immunology, 11st International Congress of Mucosal Immunology. Orlando, Florida. June 16-20, 2002. (# 2391).

17. K. Jeong, H. Suzuki, L. Saif, K. Doi. Differential adherence and transport of inhaled materials by membranous (M) cells in nasal-associated lymphoid tissue (NALT) of rat. Society for Mucosal Immunology, 11st Int`l Congress of Mucosal Immunology. Orlando, FL. June 16-20, 2002. (# 2411).

18. M. Azevedo, C. Iosef, K. Jeong, A. Gonzalez, F. Agarib, K. Chang, K. Lovgren-Bengtsson, B. Morein, P. Nielsen, T. Van Nguyen & L. J. Saif. Antibody secreting cell responses and protection in gnotobiotic pigs vaccinated orally with attenuated rotavirus and intranasally with 2/6-rotavirus-like-particles and immunostimulating complexes. The American Society for Virology, 21st Annual Meeting. University of Kentucky, Kentucky, USA. July 20-24, 2002. (# W7-4).

19. A. Gonzalez, T. VanNguyen, M. Azevedo, K. Jeong, F. Agarib, C. Iosef, K. Chang, P. Lewis, K. Lovgren-Bengtsson, B. Morein, and L. J. Saif. Vaccination of gnotobiotic pigs orally with attenuated human rotavirus (AttHRV) and intranasally with VP2/6 rotavirus-like-particles and ISCOM induces similar protection rates but higher antibody titers than AttHRV alone. The American Society for Virology, 21st Annual Meeting. University of Kentucky, Kentucky, USA. July 20-24, 2002. (# W7-5).

20. K. Jeong, A. Gonzalez, C. Iosef, M. Azevedo, T. VanNguyen, K. Chang, F. Agarib, K. Lovgren-Bengtsson, B. Morein, and L. J. Saif. Lymphoproliferative responses in gnotobiotic pigs inoculated orally with attenuated human rotavirus and intranasally with 2/6-rotavirus-like-particles with immunostimulating complexes. The American Society for Virology, 21st Annual Meeting. University of Kentucky, Kentucky, USA. July 20-24, 2002. (# W7-6).

21. Saif LJ, Yuan LJ, Azevedo MSP, Jeong KI, Gonzalez AM, Iosef C, Van Nguyen T, Herrmann JE. Protective immunity induced by live attenuated (Att) human rotavirus (HRV) priming and bovine rotavirus VP6 DNA boosting in a gnotobiotic (Gn) pig model. The American-Association-for-Immunologists, 90th Annual Meeting. Denver, Colorado, USA. May 6-10, 2003. (#669TR).

22. K. Jeong, M. S. P. Azevedo, T. Nguyen, A. Gonzalez, C. Iosef, K. Chang, L. Yuan, J. E. Herrmann, L. Saif. Cellular immune responses and protection in gnotobiotic pigs vaccinated with a VP6 DNA plasmid vaccine regime with and without attenuated human rotavirus (HRV). The American Society for Virology, 22nd Annual Meeting. University of California, Davis, USA. July 12-16, 2003. (# W47-4).

23. L. Yuan, M. Azevedo, T. Nguyen, A. Gonzalez, K. Jeong, K. Chang and L. Saif. Booster effects of rotavirus 2/6 virus-like particle (VLP) vaccine on antibody responses to rotavirus outer-capsid proteins VP4 and VP7 primed by oral attenuated human rotavirus (AttHRV) vaccine in gnotobiotic pigs. The American Society for Virology, 22nd Annual Meeting. University of California, Davis, USA. July 12-16, 2003. (# W47-5).

24. M. Azevedo, K. Jeong, T. Nguyen, A. Gonzalez, P. Nielsen, P. Lewis, K. Lovgren-Bengtsson, B. Morein, L. Yuan & L. Saif. Protective immunity in gnotobiotic (Gn) pigs after intranasal (IN) or oral priming with attenuated human rotavirus (AttHRV) and boosting with 2/6-rotavirus-like-particles (VLPs) and immuno-stimulating complexes (ISCOM), and detection of nasal shedding of AttHRV. The American Society for Virology, 22nd Annual Meeting. University of California, Davis, USA. July 12-16, 2003. (# W47-3).

25. T. Nguyen, M. Azevedo, K. Jeong, A. Gonzalez, C. Iosef, K. Lovgren-Bengtsson, B. Morein, P. Lewis, L. Yuan & L. Saif. Effect of circulating maternal antibodies on immune responses and protection induced by immunostimulating complexes (ISCOM)-VP2/6 rotavirus-like-particle (VLP) vaccine. The American Society for Virology, 22nd Annual Meeting. University of California, Davis, USA. July 12-16, 2003. (# W47-2).

26. L. Yuan, M. S. P. Azevedo, K-I. Jeong, T. V. Nguyen, A. M. Gonzalez, C. Iosef, J. E. Hermann, L. Saif. Evaluation of a live attenuated (Att) human rotavirus (HRV) priming and bovine rotavirus VP6 DNA boosting vaccination strategy in a gnotobiotic (Gn) pig model. 8th International Symposium on Double-Stranded RNA Viruses. Il Ciocco, Castelvecchio Pascoli, Italy. September 13-18, 2003. (# PR.4).

27. L. J. Saif, M. S. P. Azevedo, L. Yuan, K. I. Jeong, T. V. Nguyen, S. M. Pouly, M. Gochnauer. Nasal and rectal shedding and viremia in the gnotobiotic piglets after oral or intranasal inoculation with human rotavirus. 8th International Symposium on Double-Stranded RNA Viruses. Il Ciocco, Castelvecchio Pascoli, Italy. September 13-18, 2003. (# W6-3).

28. M. S. P. Azevedo, S. Pouly, L. Yuan, K. I. Jeong, A.M. Gonzales, T. V. Nguyen, L. J. Saif. Cytokine responses in serum and intestinal contents of gnotobiotic pigs after infection with virulent or attenuated human rotavirus (HRV). The American Society for Virology, 23rd Annual Meeting. McGill University, Montreal, Quebec, Canada. July 10-14, 2004. (# W47-4).

29. T. Nguyen, L. Yuan, M. Azevedo, K. Jeong, A. Gonzales, K. Lovgren-Bengtsson, B. Morein, P. Lewis, L. J. Saif. Effects of maternal antibodies on effector and memory B cell responses to rotavirus vaccine. The American Society for Virology, 23rd Annual Meeting. McGill University, Montreal, Quebec, Canada. July 10-14, 2004. (# W47-5).

30. Lijuan Yuan, Kwang-il Jeong, Trang V. Nguyen, Ana Gonzales, Marli S. Azevedo, Wei Zhang, L. J. Saif. Effects of maternal antibodies on T cell responses to rotavirus vaccines. The Am. Society for Virology, 23rd Annual Meeting. McGill University, Montreal, Quebec, Canada. July 10-14, 2004. (# W47-6).

31. Sonia M. Cheetham, Menira Souza, Sheila Grimes, Myung Guk Han, Qiuhong Wang, Tea Meulia, Kwang-il Jeong, Linda J. Saif. Pathogenesis of a human norovirus in the gnotobiotic pig model. The American Society for Virology, 24th Annual Meeting. The Pennsylvania State University, University Park, PA, USA. June 18-22, 2005. (# W50-8).

32. Kwang Il Jeong, Marli Azevedo, Ana Gonzalez, Trang Nguyen, Lijuan Yuan, Linda Saif. Cell-mediated immune responses in gnotobiotic pigs immunized with sequential attenuated human rotavirus (AttHRV) and 2/6-rotavirus-like particle vaccines and challenged with virulent HRV. The American Society for Virology, 24th Annual Meeting. The Pennsylvania State University, University Park, PA, USA. June 18-22, 2005. (# W33-5).

33. Gonzalez A.M, Yuan L.J, Azevedo M.P, Nguyen T.V, Jeong K, Lovgren-Bengtsson K, Morein B, and Saif L.J. B cell responses elicited by oral/intranasal (IN) immunization of gnotobiotic pigs with a rotavirus-like particle prime/boost vaccine. Society for Mucosal Immunology, International Congress of Mucosal Immunology (ICMI), 12th Annual Meeting. Boston Marriott Copley Place, Boston, Massachusetts, USA. June 25-30, 2005. (# 53008).

34. Yuan L, Nguyen T.V, Azevedo M.S, Gonzalez A.M, Jeong K, and Saif L.J. Maternal cytokines in serum and intestinal contents of suckling pigs. Society for Mucosal Immunology, International Congress of Mucosal Immunology (ICMI), 12th Annual Meeting. Boston Marriott Copley Place, Boston, Massachusetts, USA. June 25-30, 2005. (# 51459).

35. A. S. Sheoran, KI Jeong, A. Wiffin, S. Liu, S. Champman-Bonofiglio, S. Tzipori. C. hominis-specific immunity provides partial protection against C. parvum in the gnotobiotic piglet model. American Society for Microbiology, 107th General Meeting. Metro Toronto Convention Centre, Toronto, Canada. May 21-25, 2007. (# E-053).

36. Jody Schumacher, Jean Mukherjee, Kwang-il Jeong, Nicola Parry, Sue Chapman-Bonofiglio, Saul Tzipori, and Abhineet Sheoran: Monoclonal antibody therapy following lethal Shiga toxin injection in mice. Merck-Merial National Veterinary Scholars Symposium. NIH campus, Bethesda, MD. August 1-4, 2007.

37. K. Jeong, Q. Zhang, J. Nunnari, J. Mukherjee, A. Sheoran, N. Parry, A. Donohue-Rolfe, S. Tzipori. Gnotobiotic Piglet Model of Shigellosis. The American College of Veterinary Pathologists, 58th Annual Meeting. Savannah, International Trade and Convention Center and the Westin Savannah Harbor Golf Resort and Spa, Savannah, Georgia, USA. November 10-14, 2007. (# E-4).

38. Kwang Il Jeong, Jean Mukherjee, Saul Tzipori, Abhineet Sheoran. Clearance Mecahnism of Shigatoxin 2 by Human Monoclonal Antibody 5C12 Hybridoma. The American Society for Microbiology, 108th General Meeting, Boston Convention and Exposition Center, Boston, MA, USA, June 1-5, 2008. (# B-065).

39. Kwang-il Jeong, Arthur Donohue-Rolfe, Saul Tzipori. Cytokine Responses following Infection of Shigella dysenteriae type 1 in Gnotobiotic Piglet Model. Federation of Clinical Immunology Societies, 8th Annual Meeting, Boston Marriott Copley Place, Boston, MA, USA, June 5-9, 2008. (# Sa.121).

40. Kwang-il Jeong, Shoshana Barnoy, Malabi Venkatesan, Saul Tzipori. Histopathology and cytokine responses following oral infection with Shigella sonnei strains in gnotobiotic piglets. International Congress of mucosal Immunology (ICMI), 14th Annual Meeting, Boston, Boston, MA, USA, July 5-9, 2009. (# T.75).

41. Kwang-il Jeong, Shoshana Barnoy, Malabi Venkatesan, Saul Tzipori. Assessment of the safety issues of live attenuated Shigella vaccine candidates in gnotobiotic piglet model. Food & Waterborne Diseases Integrated Research Network, Annual Meeting, June 1-4, 2010. MD, USA.

42. Ryan T. Ranallo, Shoshana Barnoy, Akamol E. Suvarnapunya, MAJ James E. Lee, Lisa Bedford, Tara Boren, Suramya Fonseka, Kwang-il Jeong, Saul Tzipori, and Malabi M. Venkatesan. Live Attenuated Vaccines for Shigellosis. The Army Science Conference. Nov 29-Dec 2, 2010. Orlando, FL.

43. Kwang-il Jeong, Shoshana Barnoy, Malabi Venkatesan, Saul Tzipori. Safety assessment of virulent Shigella sonnei and live attenuated vaccine candidate strains in the gnotobiotic piglet model. Infectious Disease Sciences / Virology Annual Conference, Seattle, WA, Oct 27-Nov 1, 2010.

Contact this candidate